恒瑞医药(01276)子公司HRS9531注射液上市许可申请获受理

Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the drug listing application of HRS9531 injection, indicating progress in the company's product pipeline [1] Group 1: Product Information - HRS9531 injection is intended for long-term weight management in adults with a body mass index (BMI) of ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver [1]